Key result
NIP-142 at 100 µM prolonged atrial action potential duration without prolonging ventricular APD, acting via blockade of the IKACh current.
Why the study?
Does NIP-142 prolong refractory period and action potential duration in isolated guinea pig myocardium and block I(KACh) in Xenopus oocytes?
Does NIP-142 prolong refractory period and action potential duration in isolated guinea pig myocardium and block I(KACh) in Xenopus oocytes?
NIP-142 selectively prolongs atrial refractory period and action potential duration via I(KACh) blockade without reverse frequency dependence, highlighting its potential for treating supraventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for atrial-selective IKACh blockade in supraventricular arrhythmias; leaves open human translation and safety.
NIP-142 is a novel benzopyran compound that was shown to prolong the atrial effective refractory period and terminate experimental atrial fibrillation in the dog. In the present study, we examined the effects of NIP-142 on isolated guinea pig myocardium and on the G-protein-coupled inwardly rectifying potassium channel current (acetylcholine-activated potassium current; I(KACh)) expressed in Xenopus oocytes. NIP-142 (10 and 100 microM) concentration-dependently prolonged the refractory period and action potential duration in the atrium but not in the ventricle. E-4031 and 4-aminopyridine prolonged action potential duration in both left atrium and right ventricle. Prolongation by NIP-142 of the atrial action potential duration was observed at stimulation frequencies between 0.5 and 5 Hz. In contrast, the prolongation by E-4031 was not observed at higher frequencies. Tertiapin, a blocker of I(KACh), prolonged action potential duration in the atrium but not in the ventricle. NIP-142 completely reversed the carbachol-induced shortening of atrial action potential duration. NIP-142 (1 to 100 microM), as well as tertiapin (0.1 to 100 nM), concentration-dependently blocked I(KACh) expressed in Xenopus oocytes; the blockade by NIP-142 was not affected by membrane voltage. In conclusion, NIP-142 was shown to prolong atrial refractory period and action potential duration through blockade of I(KACh) which may possibly explain its previously described antiarrhythmic activity. NIP-142 has pharmacological properties that are different from classical class III antiarrhythmic agents such as atria specificity and lack of reverse frequency dependence, and thus appears promising for the treatment of supraventricular arrhythmia.
No takes yet. Share an insight, caveat, or question.
Matsuda et al. (2005) studied Atrial fibrillation (preclinical model). NIP-142 vs. Vehicle/Control (absence of drug) was evaluated on Atrial action potential duration at 90% repolarization (APD90) at 100 µM (p=<0.01). NIP-142 at 100 µM prolonged atrial action potential duration without prolonging ventricular APD, acting via blockade of the IKACh current.
Synapse has enriched 10 related papers. Consider them for comparative context: